May 29, 2026

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

May 27, 2026

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Conexiant

May 27, 2026

Wastewater Study Tracks Illicit Drug Use Across England

A year-long LC-MS/MS study suggests wastewater surveillance can reveal shifts in drug consumption linked to public events, weekends, and law enforcement activity

The Analytical Scientist

May 26, 2026

Semaglutide Reduced Nicotine Craving in Small Trial

Phase 2a trial found reduced nicotine craving and weight loss with semaglutide, but no significant between-group difference in cigarettes smoked per day.

Conexiant

May 11, 2026

Side Effects: Nobody Trained for This

Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.

Conexiant

May 08, 2026

Digital Twin Model May Improve Alcohol Intake Reconstruction

Integrated biomarker framework supports evaluation of drinking scenarios in forensic settings

Conexiant

May 08, 2026

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.

Conexiant

May 08, 2026

Amputation Rates Rose in Opioid-Related Hospitalizations

National inpatient analysis found steeper increases in amputations during opioid-related hospitalizations, particularly in the Northeast and West.

Conexiant

May 07, 2026

Psilocybin for Cocaine Use: Signal or Noise?

Pilot randomized study suggests possible benefit, but blinding concerns and limited generalizability complicate interpretation

Conexiant

May 06, 2026

Semaglutide Tested in Alcohol Use Disorder

Randomized trial found improvements in alcohol consumption and metabolic outcomes, with gastrointestinal adverse events more common with treatment

Conexiant